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Abstract  
A nurse-led intervention, Daily Enhancement of Meaningful Activities (DEMA), was evaluated 
for feasibility and effect sizes in a two-group randomized pilot study with 36 MCI patient-
caregiver dyads (17 DEMA and 19 attention control). Effect sizes were estimated on 10 
outcomes: dyad functional ability awareness congruence; patients’ meaningful activity 
performance satisfaction, confidence, depressive symptoms, communication satisfaction, 
physical function, life satisfaction; and, caregivers’ depressive symptoms and life changes. High 
feasibility of DEMA was supported by the following indicators: consent, 97.7%; session 
completion, 91.7%; Time 3 measure completion: 97.2 %. Compared to the attention control 
group, the DEMA group had higher dyad congruence in functional ability awareness and life 
satisfaction three months after the intervention and improved physical function at two weeks 
after the intervention. Although DEMA showed high feasibility and benefits on some health-
related outcomes, further testing of DEMA in a larger randomized controlled clinical trial is 
needed. 
 
Key Words: Clinical trial, mild cognitive impairment, caregivers, feasibility studies, depressive 
symptoms, quality of life.  
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Background  
Alzheimer’s disease (AD) is considered a global health crisis and a major health problem 
in the United States, and it is the sixth leading cause of death (Alzheimer Association, 2015). 
Mild cognitive impairment (MCI) has been described as an early symptom of AD, and patients 
with MCI are at higher risk for developing AD (Albert et al., 2011).  As the population ages, the 
prevalence of MCI is also increasing since nearly 20% of older adults in the United States 
experience MCI (Wadley et al., 2011). MCI is characterized by cognitive decline that is greater 
than expected for an individual’s age and education level but does not significantly interfere with 
everyday function (Albert et al., 2011). It is associated with other problems such as increasing 
neuropsychiatric symptoms, declining functional abilities, and impaired social relationships 
(McIlvane, Popa, Robinson, Houseweart, & Haley, 2008). In addition, no disease-altering 
treatment for MCI or AD has been found. Thus, increasing national attention is being focused on 
non-pharmacological interventions for patients with MCI and their families, as well as clinical 
trials to improve their health-related outcomes and delay the progression (National Plan to 
Address Alzheimer's Disease: 2015 Update, 2015).  
People with MCI are at high risk for decreased physical function, emotional distress, and 
depressive symptoms, and they often experience problems in communicating with their spouses 
and others (Panza et al., 2010). Their increasing emotional distress and poor life satisfaction 
often occur in concert with increasing awareness of declines in functional ability, which often 
results in disengagement from the daily meaningful activities they once enjoyed (Weiss et al., 
2012). Additionally, incongruence between people with MCI and their caregivers in their 
assessment of level of functional ability may contribute to caregiver anticipatory grief, high 
levels of subjective caregiving burden, negative psychological outcomes, and increased conflict 
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in their relationships (Seeher, Low, Reppemund, & Brodaty, 2013). MCI caregivers could be 
targeted earlier in their caregiving career by providing early behavioral interventions that may 
lead to prevention of negative outcomes. Thus, providing such early interventions for people 
with MCI and their caregivers may also be cost-effective over the long trajectory of the illness. 
Early behavioral interventions could provide a window of opportunity to assist people 
with MCI and their caregivers to learn ways to remain engaged in meaningful activities, which in 
turn may also help address changes in relationships, mood, and quality of life and slow the rate 
of cognitive decline (Boyle et al., 2012). Such interventions may also enhance decision-making 
regarding the future and reduce the health care burden to society over time.  
Existing interventions for people with MCI and their caregivers often focus on single 
problems, such as physical activity (Simon, Yokomizo, & Bottio, 2012; Suzuki et al., 2013). The 
absence of multi-faceted supportive care interventions for people with MCI and their caregivers 
is striking, especially given that interventions are most likely to be beneficial during this early 
stage of decline. The Daily Engagement in Meaningful Activities (DEMA) intervention, 
intended to be delivered by a registered nurse, is structured to provide caregivers an opportunity 
to articulate emotional needs and work with their MCI care receiver to achieve mutually agreed-
upon decisions about an activity plan that addresses the patient’s needs. The DEMA intervention 
may also reduce caregivers’ depressive symptoms and lead to positive life changes for them by 
sharing positive activity engagement and feelings with their care receiver with MCI.  
The purpose of this randomized controlled pilot study was to evaluate the feasibility and 
estimate the effect sizes of DEMA. We hypothesized that the benefits to the person with MCI 
would be reduced depressive symptoms and improved satisfaction with communication, physical 
function, and life satisfaction by increasing dyad congruence regarding assessment of the 
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condition as well as the person with MCI’s meaningful activity engagement and sense of 
confidence.  
___________________________________ 
Insert Figure 1 about here 
____________________________________ 
Conceptual Framework  
The DEMA conceptual framework (Figure 1) was developed based on: gerontological 
theory (Lawton, 1990), the Model of Human Occupation (Kielhofner, 2002), components of 
Problem-Solving Therapy (PST) (Unützer et al., 2002), and  findings from two phenomenology 
studies of patients living with MCI and their caregivers and a three-phase DEMA intervention 
development study (Lu & Haase, 2009; Lu, Haase, & Farran, 2007; Lu, Haase, & Weaver, 
2013). Based on the framework, the DEMA intervention has several features. First, DEMA 
involves assessing levels of awareness of functional ability and directing patient-caregiver dyads 
towards reconciling differences in perceptions and planning for the future. Reconciling 
differences in perceptions and opportunities for communication, exploration, and feedback about 
important topics related to planning for the future are aimed at increasing satisfaction with 
communication. Second, Problem Solving Therapy (PST) is used to assist the dyads to identify 
and achieve goals, problem-solve relative to barriers, and increase high priority activity 
participation, which is, in turn, aimed at improving the confidence of people with MCI in 
initiation and completion of tasks. Third, engaging in a variety of activities improves physical 
function.  DEMA promotes engagement in several meaningful activities which, over the course 
of the intervention, it is expected to improve physical function. Fourth, DEMA increases 
autonomy by assisting patients to identify and prioritize activities they want to address first, and 
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then to share successful activity engagement experiences with family members. Thus, the sense 
of life satisfaction may be improved through holistic support to engage in meaningful activities. 
Fifth, DEMA provides an opportunity for individuals with MCI and their family caregivers to 
address their own concerns, emotional distress, and coping strategies. The interveners assist them 
to strengthen their useful coping skills and to identify and use available local and national 
resources. 
Design and Methods 
A two-group randomized, pre-post intervention design was used to evaluate the 
feasibility of the DEMA intervention and estimate effect sizes for the DEMA group compared to 
an information support (IS) attention control condition. The study was approved by the 
University’s Institutional Review Board, and a non-probability sample was recruited. The Figure 
2, Consort Participant Flow Diagram provides an overview of study activities. 
___________________________________ 
Insert Figure 2 about here 
____________________________________ 
Setting and Sample  
Patients who were a part of MCI-caregiver dyads were recruited from the Indiana 
University Alzheimer Disease Center Clinical Core Registry and Clinic in Indianapolis. 
Inclusion criteria  for patients with MCI  were: aged 60 or older and meeting the established MCI 
classification criteria (Albert et al., 2011). Patients with significant neurologic disease other than 
suspected incipient AD or with current major depression were excluded from the study. 
Caregiver inclusion criteria were: adults with primary responsibility for providing unpaid care to 
their partner, including monitoring safety and providing social support, and a score of >4 on the 
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6-item Mini Mental Status Exam (MMSE) (Callahan, Unverzagt, Hui, Perkins, & Hendrie, 
2002). Potential caregiver participants who had diagnosed bipolar disorder or untreated 
schizophrenia were excluded from the study. For inclusion, both the patient and caregiver had to 
be able to read and speak English and have access to a telephone. 
Sample recruitment and informed consent. Recruitment occurred in two phases.  For 
Phase 1, recruitment and eligibility screening, initial contact with potential study dyads was done 
via recruitment packets mailed to 149 patients with MCI and their caregivers who either were in 
the Indiana Alzheimer Disease Research Center Registry or consented to be sent information 
after receiving a DEMA brochure during a clinic visit. The results of participant recruitment and 
enrollment are provided in the Consort diagram (Figure 2).  For Phase 2, study staff did personal 
eligibility screening and consent during a follow-up phone call with the 41 dyads who met Phase 
1 eligibility.  All dyads were fully informed about the study and procedures prior to consent. One 
declined to participate due to a scheduling conflict.  The remaining 40 dyads signed individual 
consent forms and returned them by mail at least one week prior to their scheduled baseline data 
collection. Attrition of four dyads occurred following randomization to DEMA, resulting in a 
total of 36 dyads who completed intervention sessions and measures collection. (See Figure 2). 
Sample Characteristics. Baseline characteristics for patients and caregivers are 
summarized in Table 1. The sample of patients was predominantly Caucasian (87.5%), retired 
(87.5%), and male (57.5%). Most patients were in the late MCI stage (55.0%) and40% of 
patients had depressive symptom scores ≥5 on the PHQ-9 (Kroenke, Spitzer & Williams, 2001). 
Seventy percent of caregivers were female and 82.5% were Caucasian. Most caregivers were 
spouses (77.5%), retired (65.0%), and nearly one third of caregiver had depressive symptom 
scores on the PHQ-9 of five or greater (30.0%). No significant differences between the DEMA 
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and information support (IS) group were detected, except that patients in the DEMA group were 
relatively younger (mean age = 71.2 for DEMA vs. 76.5 for IS (p = 0.022). 
_________________________________________ 
Insert Table 1 about here 
_________________________________________ 
Randomization.  Immediately following completion of the baseline assessment, the 
statistician, MTW, randomized participants (N = 40 dyads) based on the MCI patient’s PHQ-9 
score and stage of MCI (early or late). Scores of ≥ 5 points on the PHQ-9 scale are considered 
mild to severe depression (Kroenke et al., 2001).  
Intervention description. The dyads in both the DEMA and the information support (IS) 
attention control groups received six bi-weekly sessions over three months (2 face-to-face in 
clinic and 4 via phone) by a study-trained nurse intervener. The interveners, two for each group, 
were blinded, and all face-to-face meetings took place in a private clinical conference room. 
_________________________________________ 
Insert Table 2 about here 
_________________________________________ 
 
DEMA Intervention. The components of DEMA are described in Table 2. DEMA is described 
in detail in another publication by Lu and her colleagues (2013). DEMA was tailored to patient 
and  caregiver congruence in level of awareness of functional ability and to their types and 
frequencies of meaningful activity and perceived barriers to engaging in these activites. DEMA 
uses the principles of problem-solving therapy and, consistent with the overall goals of this 
intervention, DEMA provided autonomy support by helping patients identify and prioritize 
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meaningful activities, identify needs and goals, generate manageable solutions, engage in self-
selected activities with family support, plan weekly activities, self-evaluate failure and success, 
and review through problem-solving as needed. The dyads also received a Self-Management 
Tool Kit of educational material to review and discuss with the intervener, and they were 
encouraged to use the DEMA activity log at home. Self-reported types of meaningful activities 
as well as frequency and duration of activities were collected at each session.  
 IS. Participants in the IS attention control group received two face-to-face meetings to 
receive an overview of what would happen in the study and an Alzheimer’s Association mild 
cognitive impairment educational brochure. They then received four biweekly follow-up social 
conversation phone calls and had the opportunity to ask questions related to the educational 
brochure.  
Study fidelity. To enhance, maintain, and track fidelity for both the DEMA intervention 
and IS groups and to ensure evaluation fidelity, we used Treatment Fidelity Checklist (TFC)  
strategies related to design, training, intervention delivery, recipient receipts, and enactment 
(Bellg et al., 2004; Borrelli et al., 2005). Based on the checklist, the following study-specific 
strategies were used:  1) use of a conceptual model that guided  tailoring of the intervention to 
meet the dyad needs and realistic goals; 2) use of a two-group randomized controlled study 
design; 3) standardized training of the nurse interveners and subsequent  demonstration of 
“satisfactory” intervention delivery skills, including ability to tailor the intervention; 4) 
standardized evaluator training; 5)  masking participants’ group assignment to DEMA or IS for 
the evaluators; 6) audio-recording of intervention and evaluation sessions; 7) evaluation of 
participant receipt of the intervention and engagement by asking dyads about their perceived 
benefits and barriers or challenges to meeting planned weekly activity goals and adherence to the 
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self-management tool kit, time and frequency of engagement in planned activities, and use of 
resources provided. Treatment fidelity for both the DEMA and IS sessions were evaluated within 
10 days after each session using a quality assurance checklist while listening to the audio tapes.  
Measures 
 Measures were selected based on acceptable and published internal reliability, 
appropriate readability for older adults, and the study model.  Measures were completed at 
baseline (Time 1), two weeks after the intervention (Time 2), and three months after the 
intervention (Time 3) via phone by research staff. The Cronbach’s alphas of the measures in this 
study were acceptable and ranged from 0.74 to 0. 93, except for the life satisfaction measure (r = 
0.53). (See Table 3). 
Patient outcome measures. Dyad congruence in functional ability awareness refers to 
the extent of agreement between MCI patient and caregiver ratings of patient functional ability as 
measured by the Dementia Deficits Scale (Snow et al., 2004). A value of 0 indicates complete 
agreement between patient and caregiver views of functional ability.  A value > 0, means that 
there was difference between patients and caregivers regarding the rating of functional ability 
awareness. Cronbach’s alphas in this study were 0.80 for both patient and caregiver. Sense of 
confidence refers to the degree of self-confidence MCI patients had about their own ability as 
measured by the Nowotny Confidence Subscale, 8 items, responded on 4-point Likert scales. The 
total scores can range from 8 to 32, with higher scores indicating greater sense of confidence 
(Nowotny, 1989). Meaningful activity performance and satisfaction  of MCI patients as they 
engaged in self-identified meaningful activities (classified into five categories: personal care, 
physical, leisure quiet, productive, and social) were measured by the two subscales from the 
Canadian Occupational Performance Measure, two items on a 10-point response scale 
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(Kielhofner, 2002). Higher scores reflect, respectively, greater meaningful daily activities 
performance and satisfaction. Patients choose up to three meaningful activities and these 
activities could be different across time and across patients. Therefore, reliability could not be 
evaluated in this study.  Depressive symptoms refer to patient self-reported depressive symptoms 
assessed by the nine-item PHQ-9 (Kroenke et al., 2001). Higher scores indicate more severe 
depressive symptoms, and the PHQ-9 clinically meaningful cutoff points for depressive 
symptoms are: none (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe 
(20-27). Satisfaction with communication refers to the degree of satisfaction with the acts of 
sharing information, ideas, or feelings among family members or friends, measured by the 
Communication and Affective Expression Subscales of Family Assessment Device, 12 items on 
4-point Likert response scales. Total scores range from 12 to 56 (Miller, Epstein, Bishop, & 
Keitner, 1985), with higher subscale scores indicating better satisfaction with family 
communication. Physical function was measured by the Alzheimer Disease Cooperative Study-
Activities of Daily Living Scale (Galasko et al., 1997), 23 items on 3-point Likert response 
scales, with total scores ranging from 0 to 53 and higher scores indicating better physical 
functioning. Life satisfaction refers to an overall assessment of feelings and attitudes about an 
individual’s own life. It was measured by the Life Satisfaction Index for the Third Age-Short 
Form, 12 items on 6-point Likert response scales, with total scores ranging from 12 to 72 (Barrett 
& Murk, 2006)  and higher scores indicating greater life satisfaction.  
Caregiver outcome measures. Caregiver outcomes included depressive symptoms and 
caregiver life changes. Caregiver depressive symptoms refers to caregiver self-reports about the 
presence of depressive symptoms, as measured by PHQ-9. Caregiver life changes were 
measured by the 15-item Bakas Caregiving Outcomes Scale addressing changes in social 
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functioning, subjective well-being, and physical health as a result of providing care. Lower 
scores indicate negative life change (Bakas, Champion, Perkins, Farran, & Williams, 2006).  
Data Analyses and Power Calculation. 
Given the primary aims of this feasibility pilot study, sample size was based on adequacy 
for effect size estimation, given an estimated 10% attrition rate. A total of 36 dyads were in the 
pilot study, which was sufficient for conducting and exploring feasibility and effect size 
estimation (Kraemer, Mintz, Noda, Tinklenberg, & Yesavage, 2006). 
The equivalence between the DEMA and IS groups was examined separately for patients 
and caregivers on demographic characteristics at baseline using Chi square or Fisher’s Exact test 
for categorical variables and t tests for continuous variables. General linear mixed models were 
used to estimate effect sizes and included time, treatment, the interaction of time and treatment, 
and significant baseline variables. Effect sizes (Cohen’s d) were calculated for the within-group 
changes in scores, and the between-group differences in changes scores. Thresholds for 
interpretation of Cohen’s d included effect sizes labeled as large (d ≥ 0.80), medium (0.50 ≤ d < 
0.79), or small (0.20 ≤ d < 0.49) (Hedges & Olkin, 1985). In addition, we report our exploratory 
analysis of effect sizes of outcomes for a sub-sample of MCI patients who had PHQ-9 scores ≥ 5 
at baseline and their caregivers, because depression is a potential clinical marker for identifying 
MCI patients  at high risk of developing AD (Lee et al., 2012). We believed it was important to 
understand the effect sizes of DEMA for the sub-sample of MCI patients who had depression 
symptoms at baseline in the mild to severe range. 
Results 
Feasibility  
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Figure 2 provides the study CONSORT flowchart. Indicators of feasibility evaluated 
included consent rate, program attendance and time, study completion rate, and time required for 
evaluation.   
Consent rate. Forty-one patients living with MCI and their caregivers were screened and 
met the recruitment criteria for participation. They were approached during an 18-month period, 
and 40 dyads consented to participate for a consent rate of 97.7 %. One dyad declined 
participation because of conflict with caregiver work schedule.  
Program attendance rate and time spent for each session. Following baseline data 
collection, a total of 36 out of 40 dyads were accrued. The attrition rate was 10%; of 36 dyads, 
33 (91.7%) completed all sessions. The average duration of each session was 46.6 (SD = 7.7 ) 
minutes for the DEMA group and 31.2 (SD = 4.7) minutes  for the IS group. 
Completed measurements rate. 100% of the dyads completed the T1 measure, 93.1% 
completed T2, and 97.2% completed T3. The reasons for incomplete measures were illness, 
weather prohibiting safe travel, patient progression to AD, and caregiver withdrawal.  
Data collection length.  The amount of time spent on data collection by MCI patients was 
similar (p = 0.106) for the DEMA (Mean = 113.2, minutes; range = 30.0 to 220.0 minutes) and IS 
groups (Mean = 88.9 minutes, range= 27.0 to 182.0 minutes). Caregiver results were also similar 
(p = 0.982) for DEMA (Mean =110.2 minutes, range = 34.0 to 162.0 minutes) and IS groups (Mean 
= 109.9 minutes; range = 38.0 to 199.0 minutes). 
Effect size  
Meaningful activity performance and satisfaction. Results are summarized in Table 3. 
Self-selected meaningful activities chosen by MCI patients varied across sections in both groups. 
For the DEMA group, the most common self-selected meaningful activities in order of 
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increasing frequency were: active recreation (e.g., walking), socialization, quiet recreation (e.g., 
crossword puzzles or reading), household management, and personal care. For the IS group, the 
most common self-selected meaningful activities in order of increasing frequency were: quiet 
recreation, household management, active recreation, socialization, and paid/unpaid work (e.g., 
volunteer work). 
Between-group effect sizes for change scores for activity performance and satisfaction at 
T2 and T3 were not compared in this study, because the patients living with MCI were allowed 
to choose up to three meaningful activities and these activities could be different across time and 
across patients.  
___________________________________ 
Table 3 about here  
_____________________________________ 
Proximal and distal outcomes.  
___________________________________________ 
Insert Table 4 about here  
____________________________________________ 
 
As shown in Table 4, the DEMA group exhibited greater dyad congruence at Time 3, 
with a small effect size, compared to the IS group. Among patient outcomes, the DEMA group 
demonstrated a small positive effect relative to IS on physical function at Time 2, and life 
satisfaction at Time 3. Other small effect sizes favored the IS group: depressive symptoms at 
Time 3 as well as satisfaction with communication at Time 2 and Time 3. Among caregiver 
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outcomes, a moderate effect size favoring the IS group was exhibited at Time 2 for depressive 
symptoms and a small effect size at Time 3 for life change. 
Subset analysis. Subset analyses were conducted for the patients with MCI and 
caregivers who had depressive symptoms in the mild to severe range at baseline (i.e., PHQ-9 > 
5) (see Table 5). In the subset, the DEMA group had a moderate positive effect size at Time 2 on 
(i.e., greater dyad congruence) and a small effect size at Time 3.  Patients in the DEMA group 
also had a small effect size (i.e., minimally less depressive symptoms) at Time 2 and Time 3; a 
large effect size (i.e., better physical function) at Time 2 and a moderate effect size at Time 3, 
and a small effect (i.e., minimally higher life satisfaction sizes at Time 2 and Time 3). .Patients 
in the IS group had large effect sizes (i.e., greater satisfaction with communication) at Time 2 
and Time 3.  Among caregiver outcomes, the DEMA group had a small effect size (i.e., 
minimally less depressive symptoms) at Time 3, and a small effect size (i.e., minimally fewer life 
changes) at Time 2. The IS caregiver group had a small effect size (i.e., minimally less 
depressive symptoms) at Time 2 and a moderate effect size (i.e., more positive life changes at 
Time 3).  
___________________________________ 
Insert Table 5 about here  
____________________________________ 
Discussion  
Aligning with the current movement towards incorporating the concepts of dementia- 
friendly, dementia-capable, and dementia-positive health into healthcare and community 
services (Lin & Lewis, 2015), the DEMA intervention focuses on familiar and valued activities 
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important to patients with MCI  .  DEMA also assists dyads to learn ways to continue to engage 
in meaningful activities by using problem-solving techniques.  
Feasibility 
The findings from this study show that the pilot study design, methods, measures, and 
interventions are feasible for MCI patients and their family caregivers. The consent rate of 97.7% 
was higher than expected. We also had high participant retention, high program completion rate, 
and high measure completion rates at all three measurement time points. Reasons for declining to 
participate in our study, especially having secondary illnesses, are consistent with other studies 
(Mody et al., 2008).  
Outcomes for patients with MCI.   
In addition to establishing feasibility, the aim of this pilot study was to explore effect 
sizes of the DEMA intervention compared to the information support, low-dose control. Even 
considering the small sample size, it was surprising that, within the DEMA group, effect sizes for 
patients with MCI and caregiver groups were quite small or even negligible for all outcomes; 
and, for both the DEMA and IS groups, most of the effect sizes showed inconsistent patterns of 
improvement. Possible reasons for the small, negligible, and/or inconsistent effect sizes were that 
the length of time participants were followed was too short for changes to be detected and/or the 
sample was too small.  It is clear that future studies will need to consider the evaluation 
timeframe and having booster sessions. The findings also raised questions that have implications 
for future research design; a usual care group may be a better comparison group, since any 
attention given to patients with MCI and caregivers may produce unsustainable effects. Also, 
future studies should explore the kinds and patterns of skill acquisition that occur for the 
meaningful activities patients with MCI selected and enacted in the DEMA group; these 
Feasibility and Effect Sizes of DEMA 
17 
 
activities, though assumed to be positive, may at first be difficult to learn and potentially cause 
some distress. 
In reflecting on our findings, given the high percentages of patients with MCI and 
caregiver depressive symptom scores ≥ 5, we further explored the impact of depressive 
symptoms on our ability to detect changes over time (i.e., effect size). This led us to conduct the 
secondary analysis on a sub-sample of participants with mild to severe depression (PHQ-9 > 5). 
Surprisingly, even with a very small sample (n = 7), effect sizes in the sub-sample of patients and 
caregivers in the DEMA groups showed more improvement than the full sample of patients and 
caregivers in the DEMA group. These outcomes include improvement in dyad congruence in 
awareness of functional ability at Time 3, sense of confidence, depressive symptoms, physical 
function, and life satisfaction at both Time 2 and Time 3. In the sub-sample, compared to the IS 
group, physical function and life satisfaction were better in the DEMA patients  at both Time  
and Time 3; depressive symptoms were better at Time 3 and life changes better at Time 2 in the 
DEMA caregiver group.   These improvements indicate that DEMA may potentially provide 
even more benefits for those MCI patients and their family caregivers with depressive symptom 
scores > 5 and their family caregivers. 
Clinical implications. Although our study sample size was small and will need 
evaluation in a larger study, strong evidence of the feasibility and the potential benefits to both 
patients with MCI and their caregivers was found.  Nurses caring for patients with MCI and 
caregivers may want to consider using aspects of DEMA to provide a holistic patient- and 
family-centered approach to care for patients with MCI and caregiver dyads using a strength-
based, positive health approach that builds on the existing skills and values of these dyads.  
Specific strategies include (1) engaging the patient with MCI and caregiver to assess strengths 
Feasibility and Effect Sizes of DEMA 
18 
 
and existing abilities; (2) discussing functional deficits by asking about the dyad’s concerns, 
needs, and current use of available local resources and helping dyads to problem-solve their 
needs and/or concerns; (3) identifying  strategies to enhance communication skills between the 
patient with MCI and the caregiver, helping the dyad to focus on  the patient’s self-management 
skills through meaningful activity engagement; and  (4) acknowledging  dyad’s differing 
perspectives about memory changes through open and constructive discussion fosters 
congruence in dyad’s awareness of functional abilities and coping skills. Such discussion may 
help the dyad improve their communication skills and reduce feelings of frustration; patients 
with MCI reported feeling more capable in engaging in meaningful activities.  
 Study Limitations. There were several limitations of this study. First, the sample size 
was small. In the future, a larger, more adequately powered randomized controlled clinical trial 
is needed to test the revised DEMA intervention using an intent-to-treat design to obtain the 
potential effect of treatment. Second, the study had the potential for treatment diffusion because 
the same nurse delivered in-person or phone call sessions to some patients in both groups, due to 
a nurse intervener’s unexpected illness. Finally, the study has limited generalizability to the 
general population of MCI patients in MCI-caregiver dyads due to potential biases introduced by 
self-selection. Future studies should consider oversampling of minority patients living with MCI 
and caregivers, as well as conducting the study with a more ethnically diverse sample. 
   
Conclusion  
Based on recommendations from the literature (Lin & Lewis, 2015; Roland & Chappell, 
2015), the DEMA intervention was designed to be a multicomponent program using a family 
dyad approach to address priority needs for engaging in meaningful activity and focusing on 
familiar and valued activities important to patients with MCI. Using DEMA, the nurse intervener 
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was able to assist the dyads to learn ways to continue engaging in meaningful activities by using 
problem-solving techniques. This intervention not only addresses the needs of MCI patients 
regarding engaging in daily meaningful activities, but also addresses caregiver needs related to 
their personal response to providing care and living with a person with MCI. In this pilot study, 
the DEMA intervention showed high feasibility and potential benefits for health-related 
outcomes. Nurses serve an important role in ensuring that patients with MCI and their caregivers 
remain as engaged as possible in meaningful activities and in facilitating patients and caregivers 
to learn ways to effectively communicate their needs and experiences over time.  Further testing 
of an enhanced version of the DEMA intervention in a large randomized controlled clinical trial 
is needed. Nurses can serve an essential role for providing holistic patient- and family-centered 
care. They can utilize evidence-based clinical practice to improve health-related outcomes and 
quality of life and prevent premature disability for people with MCI and their family caregivers, 
as well as reduce social costs. 
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Figure 1. Conceptual Framework of the Daily Engagement of Meaningful Activities Intervention 
 
  
-Improve functional ability awareness 
- Increase autonomy support 
-Increase ability to reach achievable goals 
 - Dyad congruence in functional ability awareness 
 - Meaningful activity performance and satisfaction 
-  Sense of confidence 
 
Reduce: 
- Depressive symptoms  
   (Primary outcome) 
Improve:  
-  Satisfaction with communication  
-  Physical function  
-  Life satisfaction 
 
- Reduce depressive symptoms 
- Improve caregiver life changes 
Daily Engagement of Meaningful Activities Intervention  
(DEMA) 
 
Patient Outcomes: 
 
Caregiver outcomes 
Mediators 
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Figure 2. Consort Diagram 
 
 
 
Note: DEMA = Daily Engagement of Meaningful Activities: AD = Alzheimer’s disease; 
T1 = Time 1; T2 = Time 2; T3 = Time 3. 
  
149 dyads  
Phase 1 recruitment and eligibility 
evaluation  
40 dyads (97.5%) consented and completed baseline data collection (T1) 
 
17 dyads accrued in  DEMA  
• 15 dyads completed all sessions  
• 2 dyads intent cases  
o 1 patient illness (missed session 2) 
o 1 caregiver illness  (missed sessions 3, 4, and 5)                                                                                                         
 
17 dyads completed T2 data collection  
 
     
16 dyads and 1 caregiver completed T3 data collection and 
included data analysis 
   
18 dyads and 1 patient completed T3 data collection and 
included data analysis 
 
20 dyads assigned to DEMA 20 dyads assigned to attention control 
 
19 dyads accrued in  attention control 
• 18 dyads completed all sessions   
• 1 dyad intent case  
o Caregiver chemotherapy (missed session 2) 
1 dyad attritted 
withdrew due to winter storm 
18 dyads and 1 patient completed T2 data collection  
• 2 dyads missing data due to illness and winter storm 
1 caregiver lost to follow-up 
• 1 caregiver withdrawn  
1 patient withdrawn progressed to AD 
41 dyads  
Phase 2 eligibility evaluation and 
consent 
3 dyads attritted 
o 1 patient died, 1  caregiver illness  
      1 patient and caregiver partner separated  
 
1 dyad declined further participation 
 
Total 107 dyads excluded  
• 39 dyads unable to contact 
• 18 dyads ineligible 
• 51 dyads declined further screening 
 
40 dyads randomized 
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Table 1. Demographic Characteristics of Study Participants at Baseline in the Pilot Study 
 
 MCI patient Caregiver 
Characteristic DEMA 
N =20 
IS 
N =20 
P 
Value 
DEMA 
N =20 
IS 
N =20 
P 
Value 
Age (Year) 
    Mean (SD) 
 
71.23 (6.84) 
 
76.47 (7.05) 
 
0.022 
 
65.26 (7.23) 
 
70.47 (11.95) 
 
0.105 
Gender N (%) 
    Male 
    Female  
 
12 (60.00) 
8 (40.00) 
 
11 (55.00) 
9 (45.00) 
 
 
0.749 
 
5 (25.00) 
15 (75.00) 
 
7 (35.00) 
13 (65.00) 
 
 
0.490 
Race N (%) 
    Caucasian 
    Africa American 
    Asia 
    More than 1 Race 
 
16 (80.00) 
4 (20.00) 
0 
0 
 
19 (95.00) 
1 (5.00) 
0 
0 
 
 
 
 
0.342 
 
14 (70.00) 
4 (20.00) 
1 (5.00) 
1 (5.00) 
 
19 (95.00) 
1 (5.00) 
0 
0 
 
 
 
 
0.107 
Education (Year) 
    Mean (SD) 
 
16.80 (4.06) 
 
16.15 (3.91) 
 
0.609 
 
15.40 (3.23) 
 
15.85 (2.60) 
 
0.631 
Relationship to MCI patient 
    Spouse 
    Friends or others 
 
N/A 
N/A 
 
N/A 
N/A 
 
N/A 
N/A 
 
15 (75.00) 
5 (25.00) 
 
16 (80.00)  
4 (20.00) 
 
 
0.705 
Employment N (%)  
    Employed, Full Time 
    Employed, Part Time 
    Retired 
    Non Employed 
 
2 (10.00) 
1 (5.00) 
17 (85.00) 
0 
 
1 (5.00) 
1 (5.00) 
18 (90.00) 
0 
 
 
 
 
>0.999 
 
3 (15.00) 
2 (10.00) 
13 (65.00) 
2 (10.00) 
 
6 (30.00) 
1 (5.00) 
13 (65.00) 
0 
 
 
 
 
0.448 
MCI Stage N (%) 
    Early MCI 
    Late MCI 
 
8 (40.00) 
12 (60.00) 
 
10 (50.00) 
10 (50.00) 
 
 
0.525 
 
N/A 
N/A 
 
N/A 
N/A 
 
N/A 
N/A 
PHQ-9 (total score ≥ 5) N (%) 
    Yes 
    No 
 
7 (35.00) 
13 (65.00) 
 
8 (42.10) 
11 (57.90) 
 
 
0.648 
 
4 (20.00) 
16 (80.00) 
 
8 (40.00) 
12 (60.0) 
 
 
0.168 
Note: MCI = mild cognitive impairment; DEMA: Daily Engagement Meaningful Activity (DEMA) group; IS = 
Information Support; PHQ-9 = Patient Health Questionnaire-9. 
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Table 2. The Components of Daily Engagement of Meaningful Activity (DEMA) 
 
Session 1: Introduction 
• Introduce Self-management Tool Kit: focused on planning meaningful activity 
• Meaningful activities engagement overview and assessment: (Functional ability 
awareness) 
• Assess history of meaningful engagement 
• Identify and prioritize meaningful activities  
• Discuss potential meaningful activity goals 
• Develop a plan to enact meaningful activity  
Sessions 2-6 Part 1: Meaningful activity engagement, autonomy support, goal achievement, 
emotional needs articulation 
• Review meaningful daily activity goals: how realistic, achievable 
• Discuss potential barriers to enacting activities and prioritize needs 
• Re-evaluate decisions about priority activities  
• Establish individual daily goals  
• Identify associations between goals and planned activities 
• Choose manageable solutions/activities 
• Self-evaluate success and failure  
• Re-engage in problem-solving as needed  
• Celebrate successes and re-engage in problem solving PRN 
• Throughout, encourage patient living with MCI articulation of emotional needs  
Encourage listening by caregivers, encourage patient living with MCI to share the 
meaningfulness of activities participation 
Sessions 2-6 Part 2. Self-Management Tool Kit 5 topics (1 each session). 
Discussion of:   
2)   understanding MCI 
3)   understanding the treatment of MCI 
4)   understanding and dealing with negative emotional responses 
5)   learning strategies for living with MCI and dealing with major concerns, and  
6)   finding available local and national resources 
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Table 3. Description of Cell Means and Within- groups Effect Size for Meaningful Activity Performance and Meaningful Activity 
Satisfaction 
 
 Within-Group Effects 
 DEMA (n=20) IS  (n=20) 
Patient Proximal Outcome Meana (SE) d [95% CI] Meana (SE) d [95% CI] 
Average Score of Meaningful Activity 
Performanceb 
    
  Baseline (Time 1) 8.46 (0.27)  7.43 (0.47)  
  2 Weeks Post (Time 2) 8.42 (0.31) -0.03 [-0.25, 0.18] 8.40 (0.27) 0.40 [0.22, 0.58]* 
  3 Months Post (Time 3) 8.04 (0.27) -0.27 [-0.45, -0.09]* 8.49 (0.24) 0.42 [0.27, 0.57]* 
Average Score of Meaningful Activity 
Satisfactionb 
    
  Baseline  8.82 (0.31)  8.19 (0.42)  
  2 Weeks Post  9.24 (0.19) 0.35 [0.13, 0.56]* 8.48 (0.37) 0.12 [-0.06, 0.30] 
  3 Months Post  8.94 (0.27) 0.09 [-0.09, 0.27] 8.71 (0.28) 0.26 [0.11, 0.41]* 
Note. Daily Engagement Meaningful Activity (DEMA) group; IS = Information Support;  
aMean and SE (standard error) were estimated from the linear model with repeated measurement.  
bPatient outcomes were analyzed based on the model including age at baseline and time as covariates. Therefore, the adjusted means at each 
time point were estimated at average baseline ages 74.12.  
*Significant effect size if CI does not include zero. 
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Table 4. Description of Cell Means and Within- and Between-Groups Effect Sizes, Total Sample 
 Within-Group Effects Between-Group Effects 
Outcome 
   DEMA (n=20)
 IS (n=20)  
Proximal Outcome ra Meanb (SE) d [95% CI] Meanb (SE) d [95% CI] d [95% CI] 
  Dyad Congruence in Functional 
  Ability Awareness 
0.80      
     Baseline  4.93 (1.39)  5.70 (1.36)   
     2 Weeks Post  6.91 (1.31) -0.37 [-0.65, -0.10]* 7.13 (1.36) -0.37 [-0.64, -0.11]* -0.12 [-0.49, 0.25] 
     3 Months Post  5.14 (2.00) -0.03 [-0.29, 0.23] 7.97 (2.06) -2.78 [-3.13, -2.43]* 0.37 [-0.10, 0.85] 
  Sense of Confidence 0.93      
     Baseline  27.14 (0.89)  25.01 (0.89)   
     2 Weeks Post  27.90 (0.89) 0.17 [0.02, 0.32]* 26.25 (0.89) 0.54 [0.38, 0.68]* -0.14 [-0.31, 0.03] 
     3 Months Post  27.38 (0.89) 0.09 [-0.06, 0.24] 25.72 (0.85) 0.22 [0.07, 0.36]* -0.16 [-0.32, -0.002]* 
Patient Distal Outcome 
  Depressive Symptom  
 
0.70 
     
     Baseline  3.39 (0.92)  4.88 (0.93)   
     2 Weeks Post  3.10 (0.89) 0.09 [-0.06, 0.23] 4.10 (0.89) 0.28 [0.13, 0.43]* -0.16 [-0.33, 0.01] 
     3 Months Post  2.37 (0.86) 0.19 [0.04, 0.34]* 2.91 (0.82) 0.74 [0.59, 0.89]* -0.23 [-0.38, -0.07]* 
  Satisfaction with Communication 0.74      
     Baseline  35.87 (1.07)  34.55 (1.07)   
     2 Weeks Post  35.80 (1.01) -0.02 [-0.17, 0.13] 36.28 (1.01) 0.45 [0.30, 0.61]* -0.48 [-0.65, -0.31]* 
     3 Months Post  35.83 (1.15) -0.01 [-0.16, 0.14] 35.80 (1.11) 0.37 [0.23, 0.52]* -0.40 [-0.56, -0.24]* 
  Physical Function 0.83      
     Baseline  39.53 (1.87)  41.66 (1.92)   
     2 Weeks Post  38.69 (2.51) -0.17 [-0.33, -0.02]* 38.08 (2.63) -0.51 [-0.67, -0.34]* 0.46 [0.25, 0.66]* 
     3 Months Post  38.50 (2.04) -0.21 [-0.37, -0.05]* 40.71 (2.08) -0.26 [-0.42, -0.11]* -0.02 [-0.19, 0.16] 
  Life Satisfaction 0.53      
     Baseline  47.12 (1.51)  45.84 (1.51)   
     2  Weeks Post  49.11 (1.77) 0.31 [0.16, 0.46]* 47.95 (1.77) 0.54 [0.38, 0.69]* -0.02 [-0.19, 0.14] 
     3 Months Post  49.47 (1.50) 0.57 [0.41, 0.72]* 46.91 (1.44) 0.21 [0.07, 0.36]* 0.27 [0.12, 0.43]* 
Caregiver Distal Outcome       
  Depressive Symptom  0.72      
     Baseline  2.85 (0.76)  3.85 (0.76)   
     2 Weeks Post  3.32 (0.80) -0.18 [-0.32, 0.03] 3.02 (0.82) 0.34 [-0.49, -0.18]* -0.50 [-0.68, -0.32]* 
     3 Months Post  2.14 (0.64) 0.28 [0.13, 0.43]* 3.27 (0.62) 0.17 [0.02, 0.31]* 0.04 [-0.12, 0.20] 
  Life Changes  0.91      
     Baseline  58.85 (2.34)  55.05 (2.34)   
7 
 
     2 Weeks Post  57.97 (2.02) -0.08 [-0.22, 0.07] 55.24 (2.05) 0.04 [-0.12, 0.19] -0.12 [-0.29, 0.06] 
     3 Months Post  57.99  (2.66) -0.07 [-0.22, 0.08] 59.33 (2.60) 0.41 [0.27, 0.56]* -0.46 [-0.62, -0.29]* 
Note. Daily Engagement Meaningful Activity (DEMA) group; IS = Information Support 
ar indicates Cronbach’s alphas, the internal reliability. 
bMean and SE (standard error) were estimated from the linear model with repeated measurement.  
cPatient outcomes were analyzed based on the model including age at baseline, treatment, time, and the interaction of time and treatment 
as covariates. Therefore, the adjusted means at each time point were estimated at average ages 74.12. 
dOther outcomes were analyzed based on the model including treatment, time, and the interaction of time and treatment as covariates.  
*Significant effect size if CI does not include zero. 
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Table 5. Description of Cell Means and Within- and Between-Groups Effect Sizes, Sub-Sample: Patients with PHQ-9 ≥ 5 at Baseline Only 
 
 Within-Group Effects Between-Group Effects 
Outcome DEMA (n=7) IS (n=8)  
Proximal Outcomes Meana (SE) d [95% CI] Meana (SE) d [95% CI] d [95% CI] 
  Dyad Congruence in Functional  
  Ability Awarenessb 
     
     Baseline 5.00 (1.58)  5.00 (2.57)   
     2 Weeks Post 5.50 (3.50) -0.14 [-1.18, 0.91] 9.00 (1.15) -1.15 [-1.85, -0.45]* 0.99 [-0.80, 2.78] 
     3 Months Post 1.80 (0.58) 1.40 [0.54, 2.25]* 3.33 (2.33) 0.29 [-0.35, 0.94] 0.38 [-0.66, 1.41] 
Patient Proximal Outcome      
  Sense of Confidencec      
     Baseline 26.86 (1.64)  23.00 (1.53)   
     2 Weeks Post 27.87 (1.63) 1.21 [0.59, 1.83] 23.83 (1.48) 0.31 [-0.10, 0.73] 0.09 [-0.47, 0.65] 
     3 Months Post 27.45 (1.24) 0.23 [-0.33, 0.80] 23.27 (1.12) 0.17 [-0.25, 0.58] 0.16 [-0.40, 0.72] 
Patient Distal Outcomec 
  Depressive Symptom (PHQ-9) 
     
     Baseline 8.29 (1.39)  8.75 (1.30)   
     2 Weeks Post 5.09 (1.51) 0.80 [0.21, 1.39]* 7.48 (1.29) 0.30 [-0.12, 0.71] 0.46 [-0.11, 1.04] 
     3 Months Post 3.28 (1.14) 1.26 [0.64, 1.89]* 5.34 (0.97) 1.02 [0.58, 1.46]* 0.44 [-0.13, 1.01] 
  Satisfaction with Communication      
     Baseline 37.29 (2.34)  31.88 (2.18)   
     2 Weeks Post 36.80 (2.32) -0.12 [-0.68, 0.44] 35.09 (2.06) 0.73 [0.30, 1.16]* -0.87 [-1.47, -0.28]* 
     3 Months Post 34.68 (2.10) -1.13 [-1.75, -0.52]* 33.38 (1.91) 0.48 [0.06, 0.90]* -1.45 [-2.10, -0.81]* 
  Physical Function      
     Baseline 39.29 (4.29)  42.57 (4.29)   
     2 Weeks Post 41.14 (4.06) 0.48 [-0.09, 1.05] 40.04 (4.00) -0.62[1.12, -0.12]* 1.10 [0.46, 1.74]* 
     3 Months Post 39.46 (3.88) 0.07 [-0.49, 0.63] 40.89 (3.86) -0.65 [-1.15, -0.15]* 0.74 [0.13, 1.35]* 
  Life Satisfaction      
     Baseline 47.43 (3.16)  45.00 (2.95)   
     2 Weeks Post 49.64 (2.60) 0.71 [0.13, 1.29]* 46.37 (2.37) 0.36 [0.05, 0.78]*  0.24 [-0.33, 0.80] 
     3 Months Post 49.84 (2.63) 1.47 [0.83, 2.12]* 45.45 (2.36) 0.08 [-0.34, 0.49] 0.41 [-0.16, 0.98] 
Caregiver Outcome      
  Depressive Symptom (PHQ-9)      
     Baseline 3.86 (1.65)  4.75 (1.54)   
     2 Weeks Post 3.72 (1.94) 0.03 [-0.53, 0.59] 3.87 (1.80) 0.62 [0.15, 1.10]* -0.24 [-0.83, 0.35] 
     3 Months Post 1.09 (0.78) 1.55 [0.90, 2.20]* 3.25 (0.72) 0.35 [-0.12, 0.82] 0.38 [-0.22, 0.38] 
  Life Changes       
     Baseline 54.86 (4.00)  51.88 (3.74)   
     2 Weeks Post 56.55 (4.90) 0.34 [-0.23, 0.91] 51.95 (4.56) 0.01 [-0.46, 0.48] 0.28 [-0.32, 0.87] 
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     3 Months Post 55.04 (6.68) 0.03 [-0.54, 0.59] 59.91 (6.18) 0.66 [0.18, 1.14]* -0.77 [-1.38, -0.15]* 
Note. Daily Engagement Meaningful Activity (DEMA) group; IS = Information Support; PHQ-9 = Patient Health Questionnaire-9. 
aMean and SE (standard error) were estimated from the linear model with repeated measurement, except for dyad congruence. 
bDue to small sample size, this outcome was not analyzed by linear model. The Mean (SE) and effect sizes were calculated based on the raw data.  
cOutcomes were analyzed based on the model including treatment, time, and the interaction of time and treatment as covariates. 
* Significant effect size if CI does not include zero. 
 
 
